A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

StatusRecruiting

PhasePhase 3

SponsorMerck Sharp & Dohme LLC

Started2026-06-18

View on ClinicalTrials.gov ↗

Amendment history

2026-10-02

Trial sites expanded: 84 → 91 locations

2026-09-30

Trial sites expanded: 80 → 84 locations

2026-09-22

Trial sites expanded: 73 → 80 locations

2026-09-10

Study Status, Contacts/Locations v13

Trial sites expanded: 65 → 73 locations

2026-09-05

Study Status, Contacts/Locations v12

Study sites63→65

2026-08-27

Study Status, Contacts/Locations v11

Trial sites expanded: 59 → 63 locations

2026-08-20

Study Status, Contacts/Locations v10

Trial sites expanded: 56 → 59 locations

2026-08-13

Study Status, Contacts/Locations v9

Trial sites expanded: 53 → 56 locations

2026-08-06

Study Status, Contacts/Locations v8

Study sites52→53

2026-07-30

Study Status, Contacts/Locations v7

Study sites50→52

2026-07-24

Study Status, Contacts/Locations v6

Trial sites expanded: 35 → 50 locations

2026-07-17

Study Status, Contacts/Locations v5

Study sites33→35

2026-07-08

Study Status, Contacts/Locations v4

Trial sites expanded: 25 → 33 locations

Trial sites expanded: 16 → 25 locations

2026-07-02

Study Identification, Study Status, Contacts/Locations v3

Study sites16→25

2026-06-25

Study Status, Contacts/Locations v2

Trial sites expanded: 5 → 16 locations

Start dateestimated 2026-06-05→confirmed 2026-06-18

2026-06-01

Study Status, Contacts/Locations v1

Recruitment opened

Trial sites expanded: 0 → 5 locations

2026-04-21

Original filing

Merck (MSD)

401 trials monitored

See 24 trials at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.

Trial Details

NCT Number	NCT07554339
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Non-small Cell Lung Cancer
Enrollment	310 participants
Start Date	2026-06-18
Primary Completion	2032-12-15 (estimated)
Study Completion	2037-08-17 (estimated)
Updated on ClinicalTrials.gov	2026-10-01